Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

@article{Tan2004EvaluationOB,
  title={Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.},
  author={Antoinette R. Tan and Xiaowei Yang and Stephen M. Hewitt and Arlene W. Berman and Erin R. Lepper and Alex Sparreboom and Allyson L Parr and William D. Figg and Catherine Chow and Seth Steinberg and Stephen L. Bacharach and Millie Whatley and Jorge A. Carrasquillo and Jaime S Brahim and Seth A. Ettenberg and Stan Lipkowitz and Sandra M Swain},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 15},
  pages={3080-90}
}
PURPOSE To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation and its downstream signaling in tumor and surrogate tissue biopsies in patients with metastatic breast cancer treated with erlotinib, an EGFR tyrosine kinase inhibitor, and to assess relationships between biomarkers in tumor and normal tissues and between biomarkers and pharmacokinetics. PATIENTS AND METHODS Eighteen patients were treated orally with 150 mg/d of erlotinib. Ki67, EGFR, phosphorylated EGFR… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

Similar Papers

Loading similar papers…